Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | CKS1B | P61024 | 2/20 | 0.55 |
| ▸ | SKP1 | P63208 | 2/20 | 0.55 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461584 | 0.89 | CKS1B (0.62) | MAP4K4CKS1BSKP1SKP2GPR119 | |
| SCHEMBL23839560 | 0.89 | MAP4K4 (0.55) | HRH3MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL31651832 | 0.86 | MAP4K4 (0.53) | HRH3MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL3108968 | 0.86 | MAP4K4 (0.53) | HRH3MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL441495 | 0.86 | CKS1B (0.56) | MAP4K4CKS1BSKP1SKP2GPR119 | |
| SCHEMBL29574323 | 0.86 | CKS1B (0.56) | MAP4K4CKS1BSKP1SKP2GPR119 | |
| SCHEMBL391351 | 0.85 | HRH3 (0.54) | HRH3MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL4949224 | 0.84 | CKS1B (0.57) | MAP4K4CKS1BSKP1SKP2GPR119 | |
| SCHEMBL29664252 | 0.84 | CKS1B (0.57) | MAP4K4CKS1BSKP1SKP2GPR119 | |
| SCHEMBL461585 | 0.84 | CKS1B (0.60) | MAP4K4CKS1BSKP1SKP2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | HRH3 4494/4885MAP4K4 1635/4885CKS1B 541/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | HRH3 202/4885MAP4K4 515/4885CKS1B 1157/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | HRH3 331/4885MAP4K4 2143/4885CKS1B 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.